NCT02243579 - Pembrolizumab in Treating Patients With Relapsed or Refractory Stage IB-IVB Mycosis Fungoides or Sezary Syndrome | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 15, 2014

Primary Completion Date

January 4, 2018

Study Completion Date

April 1, 2019

Conditions

Recurrent Mycosis Fungoides and Sezary SyndromeRefractory Mycosis Fungoides and Sezary SyndromeStage IB Mycosis Fungoides and Sezary Syndrome AJCC v7Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v7Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v7Stage IIIA Mycosis Fungoides and Sezary Syndrome AJCC v7Stage IIIB Mycosis Fungoides and Sezary Syndrome AJCC v7Stage IVA Mycosis Fungoides and Sezary Syndrome AJCC v7Stage IVB Mycosis Fungoides and Sezary Syndrome AJCC v7

Interventions

OTHER

Laboratory Biomarker Analysis

Correlative studies

BIOLOGICAL

Pembrolizumab

Given IV

Trial Locations (8)

10065

Memorial Sloan Kettering Cancer Center, New York

19104

University of Pennsylvania/Abramson Cancer Center, Philadelphia

21287

Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore

33612

Moffitt Cancer Center, Tampa

43210

Ohio State University Comprehensive Cancer Center, Columbus

94304

Stanford Cancer Institute Palo Alto, Palo Alto

98109

Seattle Cancer Care Alliance, Seattle

06520

Yale University, New Haven

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH